A rich heritage in business development
We have a rich heritage in business development.
We have a rich heritage in partnering with a long history of successful scientific and commercial collaborations. Partnering has been an integral part of our evolution to become a leading biopharma company – it’s part of our DNA.
As critical drivers of our strategy, external innovation and partnering have brought significant commercial success and pipeline growth. Twelve of our company’s twenty blockbuster medicines are derived from collaborations.In addition, more than sixty percent of our current development pipeline is externally sourced bringing significant external innovation to complement our internal capabilities and innovation.
Our long and proven track record of partnering exhibits speed, transparency, flexibility, creativity and above all, a focus on innovative science and delivering transformational medicines to patients.
|June 2021||Agreement with Eisai Co., Ltd for the co-development and co-commercialization of MORAb-202, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC). Learn more|
|March 2021||Partnership with bluebird bio results in FDA approval of Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma. Learn More.|
|February 2021||License agreement with The Rockefeller University to develop, manufacture and commercialize Rockefeller’s novel monoclonal antibody (“mAb”) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19. Learn More|
|November 2020||Acquisition of MyoKardia, a clinical-stage cardiovascular company with a late-stage clinical asset, mavacamten, which has the potential to be a first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (HCM) – a chronic heart disease with high morbidity and patient impact. Promising pipeline of novel compounds including 2 clinical stage therapeutics: danicamtiv and MYK-224. Learn More|
|September 2020||Acquisition of Forbius to gain access to a portfolio of highly selective and potent inhibitors of TGF-beta 1 & 3 which are key mediators of immunosuppression and fibrosis. The lead investigational asset, AVID200, is currently in Phase 1. Learn More|
|August 2020||Agreement with Dragonfly to license their IL-12 investigational immunotherapy program including its extended half-life cytokine DF6002 which is currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Learn More|
|July 2020||Research collaboration with Dragonfly to develop novel therapeutic candidates for multiple sclerosis and neuro-inflammation targets.|
|May 2020||Collaboration with Repare to identify multiple precision oncology drug candidates by leveraging Repare’s synthetic lethal discovery platform.|
|March 2020||Collaboration with Voluntis to create and investigate digital therapeutics solutions that will support cancer patients. Learn More|